Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 40 papers were listed this time. Here's a handful in our areas of research interest:
Soini E, Hallinen T, Puolakka K, et al. Cost-effectiveness of adalimumab, etanercept and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ. 2011 Dec 14. [Epub ahead of print] PubMed PMID: 22168785.
Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, et al. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health. 2011 Dec;14(8):1039-47. PMID: 22152172.
Hall PS, McCabe C, Stein RC, Cameron D. Economic Evaluation of Genomic Test-Directed Chemotherapy for Early-Stage Lymph Node-Positive Breast Cancer. J Natl Cancer Inst. 2011 Dec 2. [Epub ahead of print] PMID: 22138097.
Tran-Duy A, Boonen A, van de Laar MA, et al. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. Ann Rheum Dis. 2011 Dec;70(12):2111-8. PMID: 21857027.
